BACKGROUND: Topical corticosteroids are the standard of care in paediatric atopic dermatitis (pAD). However, messages that overstress possible side effects can have a negative impact on perceptions of safety and contribute to treatment non-adherence. The aim of this study was to assess general practitioners' (GPs') perception of the safety of topical corticosteroids in pAD treatment. METHODS: Australian GPs participating in continuing professional development programs were assessed before an education session on pAD. Responses were recorded via an electronic survey. RESULTS: A total of 257 GPs were surveyed. More than one-third (40.7%) of the GPs instructed parents to apply topical corticosteroids for two weeks or less. Nearly half (47.7%) instructed parents to apply topical corticosteroids sparingly or with the smallest amount possible. Furthermore, nearly one-third (30.2%) reported skin atrophy as the most common side effect of topical corticosteroids. DISCUSSION: Advice to patients given by Australian GPs may carry unintentional risk messages contributing to treatment non‑adherence. Evidence-based information on the safety of topical corticosteroids is needed to empower GPs to improve treatment outcomes in pAD.
BACKGROUND: Topical corticosteroids are the standard of care in paediatric atopic dermatitis (pAD). However, messages that overstress possible side effects can have a negative impact on perceptions of safety and contribute to treatment non-adherence. The aim of this study was to assess general practitioners' (GPs') perception of the safety of topical corticosteroids in pAD treatment. METHODS: Australian GPs participating in continuing professional development programs were assessed before an education session on pAD. Responses were recorded via an electronic survey. RESULTS: A total of 257 GPs were surveyed. More than one-third (40.7%) of the GPs instructed parents to apply topical corticosteroids for two weeks or less. Nearly half (47.7%) instructed parents to apply topical corticosteroids sparingly or with the smallest amount possible. Furthermore, nearly one-third (30.2%) reported skin atrophy as the most common side effect of topical corticosteroids. DISCUSSION: Advice to patients given by Australian GPs may carry unintentional risk messages contributing to treatment non‑adherence. Evidence-based information on the safety of topical corticosteroids is needed to empower GPs to improve treatment outcomes in pAD.
Authors: Anneliese Willems; Amanda Tapley; Alison Fielding; Er Tsing Vivian Tng; Elizabeth G Holliday; Mieke L van Driel; Jean I Ball; Andrew R Davey; Irena Patsan; Kristen FitzGerald; Neil A Spike; Parker J Magin Journal: Dermatol Pract Concept Date: 2021-09-01
Authors: Aviël Ragamin; Renske Schappin; Willemijn C A M Witkam; Magda Spiering; Elodie Mendels; Marie L A Schuttelaar; Suzanne G M A Pasmans Journal: Skin Health Dis Date: 2022-07-20
Authors: Anneliese Willems; Amanda Tapley; Alison Fielding; Vivian Tng; Elizabeth G Holliday; Mieke L van Driel; Jean I Ball; Andrew R Davey; Kristen FitzGerald; Neil A Spike; Parker J Magin Journal: Dermatol Pract Concept Date: 2021-01-29